WO2006002909A3 - Sphingolipids against pathological processes in lipid rafts - Google Patents

Sphingolipids against pathological processes in lipid rafts Download PDF

Info

Publication number
WO2006002909A3
WO2006002909A3 PCT/EP2005/007033 EP2005007033W WO2006002909A3 WO 2006002909 A3 WO2006002909 A3 WO 2006002909A3 EP 2005007033 W EP2005007033 W EP 2005007033W WO 2006002909 A3 WO2006002909 A3 WO 2006002909A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphingolipids
pathological processes
lipid rafts
against pathological
rafts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007033
Other languages
French (fr)
Other versions
WO2006002909A2 (en
Inventor
Tobias Braxmeier
Tim Friedrichson
Wolfgang Froehner
Gary Jennings
Georg Schlechtingen
Cornelia Schroeder
Hans-Joachim Knoelker
Kai Simons
Marino Zerial
Teymuras Kurzchalia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Dresden
JadoLabs GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Technische Universitaet Dresden
JadoLabs GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Dresden, JadoLabs GmbH, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Technische Universitaet Dresden
Priority to JP2007518535A priority Critical patent/JP2008504330A/en
Priority to AU2005259501A priority patent/AU2005259501A1/en
Priority to CA002572310A priority patent/CA2572310A1/en
Priority to US11/571,354 priority patent/US7629385B2/en
Priority to DE602005011802T priority patent/DE602005011802D1/en
Priority to EP05756574A priority patent/EP1763342B1/en
Publication of WO2006002909A2 publication Critical patent/WO2006002909A2/en
Anticipated expiration legal-status Critical
Publication of WO2006002909A3 publication Critical patent/WO2006002909A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

The present invention relates to specific sphingolipids/sphingolipid derivatives as pharmaceutical compositions as well as their use in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.
PCT/EP2005/007033 2004-06-29 2005-06-29 Sphingolipids against pathological processes in lipid rafts Ceased WO2006002909A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007518535A JP2008504330A (en) 2004-06-29 2005-06-29 Sphingolipid-derived pharmaceutical composition
AU2005259501A AU2005259501A1 (en) 2004-06-29 2005-06-29 Sphingolipids against pathological processes in lipid rafts
CA002572310A CA2572310A1 (en) 2004-06-29 2005-06-29 Sphingolipid-derived pharmaceutical compositions
US11/571,354 US7629385B2 (en) 2004-06-29 2005-06-29 Sphingolipid-derived pharmaceutical compositions
DE602005011802T DE602005011802D1 (en) 2004-06-29 2005-06-29 AFTS
EP05756574A EP1763342B1 (en) 2004-06-29 2005-06-29 Sphingolipids against pathological processes in lipid rafts

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04015248 2004-06-29
EP04015248.0 2004-06-29
US63647104P 2004-12-16 2004-12-16
US60/636,471 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006002909A2 WO2006002909A2 (en) 2006-01-12
WO2006002909A3 true WO2006002909A3 (en) 2007-03-22

Family

ID=35134634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007033 Ceased WO2006002909A2 (en) 2004-06-29 2005-06-29 Sphingolipids against pathological processes in lipid rafts

Country Status (9)

Country Link
US (1) US7629385B2 (en)
EP (2) EP2065040A3 (en)
JP (1) JP2008504330A (en)
AT (1) ATE417607T1 (en)
AU (1) AU2005259501A1 (en)
CA (1) CA2572310A1 (en)
DE (1) DE602005011802D1 (en)
ES (1) ES2317259T3 (en)
WO (1) WO2006002909A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (en) * 2001-11-21 2003-05-21 Univ Roma IMMUNOREGULATORY COMPOUNDS.
EP1618876A1 (en) * 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
WO2008111916A1 (en) * 2007-03-09 2008-09-18 Agency For Science, Technology And Research Glycosphingolipid-aided intracellular delivery of cargo molecules
DE102008002410A1 (en) * 2008-06-13 2009-12-17 Evonik Goldschmidt Gmbh Enzymatic synthesis of sphingolipids
DE102008002409A1 (en) * 2008-06-13 2009-12-17 Evonik Goldschmidt Gmbh Enzymatic synthesis of sphingolipids
US8853452B2 (en) * 2009-02-10 2014-10-07 The Administrators Of The Tulane Educational Fund Compounds, their syntheses, compositions, and methods to treat cancer
WO2012054092A1 (en) * 2010-01-22 2012-04-26 Trustees Of Dartmouth College Lipid cofactors for facilitating propogation of prpsc
US20130266977A1 (en) * 2010-02-16 2013-10-10 President And Fellows Of Harvard College Methods and systems for detection of microbes
US20130203715A1 (en) 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
RU2640921C2 (en) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Cations of monovalent metals of dry powders for inhalations
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
JP2013071918A (en) * 2011-09-28 2013-04-22 Shiseido Co Ltd Filaggrin production promoter
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
JP2015509788A (en) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド Dry powder suitable for inhalation
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
JP6438417B2 (en) * 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー Methods for the synthesis of sphingomyelin and dihydrosphingomyelin
JP6232008B2 (en) * 2015-03-19 2017-11-15 国立大学法人北海道大学 Oxidation inhibitor and oil-containing food and drink using the same
JP6661192B2 (en) * 2016-01-19 2020-03-11 国立大学法人北海道大学 Ceramide derivative having SMS2 inhibitory activity
EP3259990A1 (en) * 2016-06-20 2017-12-27 Ceva Sante Animale Methods for controlling ectoparasites in non-human mammals
DE102018217334A1 (en) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid base and / or active ingredient for use in the prophylaxis and / or therapy of a viral infection and / or viral infectious disease or disinfection, food / food supplements, feed / feed supplements and crop protection agents
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
CN115894278B (en) * 2022-11-01 2024-12-17 深圳市迪克曼生物科技有限公司 Linolenic acid-derived ceramide and preparation method and application thereof
WO2026017703A2 (en) * 2024-07-16 2026-01-22 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Multifunctional sphingomyelin and ceramide

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010991A1 (en) * 1992-11-12 1994-05-26 Carnegie Institution Of Washington Ceramide derivatives
JPH08113535A (en) * 1994-10-13 1996-05-07 Sumitomo Pharmaceut Co Ltd Neuronal degeneration or death inhibitor
WO1998002153A1 (en) * 1996-07-16 1998-01-22 The John P. Robarts Research Institute Ceramide promotors of haematopoiesis
WO1999041266A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
DE19841794A1 (en) * 1998-09-12 2000-03-16 Beiersdorf Ag Synergistic, selective antimicrobial preparation useful for treating acne and seborrheic dermatitis or as deodorant contains antiadhesive agent, e.g. ceramide, and antimicrobial agent
WO2000059517A1 (en) * 1999-04-07 2000-10-12 Roger Williams Hospital Ceramide and chemotherapeutic agents for inducing cell death
WO2004064823A1 (en) * 2003-01-21 2004-08-05 Aston University Ceramide derivatives for the treatment of inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19946737A1 (en) 1999-09-29 2001-04-19 Max Planck Gesellschaft Use of gangliosides to modulate sphingolipid cholesterol microdomains
WO2001096575A1 (en) 2000-06-14 2001-12-20 Sankyo Company, Limited Ceramide kinase and dna encoding the same
US20040004522A1 (en) 2002-07-03 2004-01-08 Sweeney Anthony C. N-way signal divider

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010991A1 (en) * 1992-11-12 1994-05-26 Carnegie Institution Of Washington Ceramide derivatives
JPH08113535A (en) * 1994-10-13 1996-05-07 Sumitomo Pharmaceut Co Ltd Neuronal degeneration or death inhibitor
WO1998002153A1 (en) * 1996-07-16 1998-01-22 The John P. Robarts Research Institute Ceramide promotors of haematopoiesis
WO1999041266A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
DE19841794A1 (en) * 1998-09-12 2000-03-16 Beiersdorf Ag Synergistic, selective antimicrobial preparation useful for treating acne and seborrheic dermatitis or as deodorant contains antiadhesive agent, e.g. ceramide, and antimicrobial agent
WO2000059517A1 (en) * 1999-04-07 2000-10-12 Roger Williams Hospital Ceramide and chemotherapeutic agents for inducing cell death
WO2004064823A1 (en) * 2003-01-21 2004-08-05 Aston University Ceramide derivatives for the treatment of inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ITO, AKIRA: "N-acylsphingosine and sphingomyelinase as inhibitors of neuron degeneration and death", XP002394743, retrieved from STN Database accession no. 1996:464360 *
DATABASE WPI Week 1996, Derwent World Patents Index; AN 1996-272724, XP002394745 *
ROSENWALD, ANNE G. ET AL: "Inhibition of glycoprotein traffic through the secretory pathway by ceramide", JOURNAL OF BIOLOGICAL CHEMISTRY , 268(7), 4577-9 CODEN: JBCHA3; ISSN: 0021-9258, 1993, XP008067575 *

Also Published As

Publication number Publication date
ATE417607T1 (en) 2009-01-15
EP1763342A2 (en) 2007-03-21
US7629385B2 (en) 2009-12-08
AU2005259501A1 (en) 2006-01-12
JP2008504330A (en) 2008-02-14
DE602005011802D1 (en) 2009-01-29
EP1763342B1 (en) 2008-12-17
WO2006002909A2 (en) 2006-01-12
ES2317259T3 (en) 2009-04-16
EP2065040A2 (en) 2009-06-03
CA2572310A1 (en) 2006-01-12
US20080090913A1 (en) 2008-04-17
EP2065040A3 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
EP2065040A3 (en) Sphingolipids against pathological processes in lipid rafts
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
WO2006124748A3 (en) Multicyclic compounds and methods of their use
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
WO2007067495A3 (en) Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2005080313A3 (en) Sulfonamide derivatives for the treatment of diseases
WO2007146085A3 (en) Creatine phosphate prodrugs, compositions and uses thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2006108582A3 (en) Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
WO2007052023A3 (en) Novel compounds
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TW200508210A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007107008A8 (en) Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
EP2746254A3 (en) Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
TW200724532A (en) Pyrimidinecarboxylic acid derivatives and their use
WO2007031883A3 (en) Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2007012479A3 (en) Benzylpiperazine derivates and their medical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2572310

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007518535

Country of ref document: JP

Ref document number: 2005259501

Country of ref document: AU

Ref document number: 4787/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005756574

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005259501

Country of ref document: AU

Date of ref document: 20050629

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005259501

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005756574

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11571354

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11571354

Country of ref document: US